Vertex Pharmaceuticals SEC filings, summarized
We read every Vertex Pharmaceuticals 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track VRTX in your inbox
Add Vertex Pharmaceuticals to your watchlist — free, every morning.
Recent filings
Vertex Adds Former Boston Scientific CFO Daniel Brennan to Board
Vertex Pharmaceuticals appointed Daniel Brennan to its board on October 20, 2026, increasing the board’s size from 10 to 11 members; he also joined the…
Vertex names Jonathan Poole CFO effective January 1, 2027
Vertex Pharmaceuticals appointed Jonathan Poole, currently its Senior Vice President of Finance, as executive vice president and chief financial officer…
Vertex raises 2026 revenue guidance after second-quarter sales rise 12%
Vertex reported second-quarter 2026 revenue of $3.33 billion, up 12% from a year earlier, with GAAP net income of $1.10 billion, or $4.31 per diluted share;…
VERTEX ($VRTX) filed Form 8‑K on Feb 12, 2026 (Item 9.01) — exhibits include Press Release (Exhibit 99.1)…
VERTEX ($VRTX) filed Form 8‑K on Feb 12, 2026 (Item 9.01) — exhibits include Press Release (Exhibit 99.1) and Cover Page iXBRL (Exhibit 104). Report signed…
Vertex ($VRTX) issued a press release on Feb 12, 2026 reporting consolidated financial results for the…
Vertex ($VRTX) issued a press release on Feb 12, 2026 reporting consolidated financial results for the three and twelve months ended Dec 31, 2025. Press…